Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(24):1852-1853; doi:10.1093/jnci/dji434
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reid, J. F.
Right arrow Articles by Pierotti, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Reid, J. F.
Right arrow Articles by Pierotti, M. A.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome

James F. Reid, Lara Lusa, Loris De Cecco, Danila Coradini, Silvia Veneroni, Maria Grazia Daidone, Manuela Gariboldi, Marco A. Pierotti

Affiliations of authors: Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy (JFR, LL, LDC, DC, SV, MGD, MG, MAP); Molecular Cancer Genetics Group, Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milano, Italy (JFR, LL, LDC, MG, MAP)

Correspondence to: James F. Reid, PhD, Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milano 20139, Italy (e-mail: james.reid@ifom-ieo-campus.it).

The first 10% of the full text of this article appears below.

We would like to comment on the correspondence by Jansen et al. concerning our recently published article (1). Jansen et al. pointed out three problems with our validation study of the HOXB13/IL17BR ratio that Ma et al. (2) reported could predict clinical outcome after tamoxifen treatment in women with estrogen receptor (ER)–positive resectable breast cancer.

1) Cohort selection. The small validation set used by Ma . . . [Full Text of this Article]

2) Definition of response. 3) Primer design.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
Maurice P. H. M. Jansen, John A. Foekens, Jan G. M. Klijn, and Els M. J. J. Berns
J Natl Cancer Inst 2005 97: 1851-1852. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. F. Symmans
Genomic testing for sensitivity of breast cancer to hormonal therapy.
Clin. Cancer Res., April 1, 2006; 12(7): 1954 - 1955.
[Full Text] [PDF]